Researchers are exploring the use of nanocarriers directed by cd44 and cd133 aptamers to target cancer stem cells. This approach aims to overcome drug resistance and tumor recurrence. The role of cd44 is also being examined in the context of sarcomas, with a review of current knowledge and potential future directions.